Blood donors screening for blood born viruses in Poland.

Blood donor screening of viral markers in Poland is based on serologic testing for anti-HCV, HBsAg, anti-HIV1/2 (chemiluminescence tests) and on nucleic acid testing (NAT) for RNA HCV, RNA HIV-1 and DNA HBV performed in minipools of 6 with real-time PCR (MPX 2.0 test on cobas s201) or with TMA in individual donations (Ultrio Plus or Ultrio Elite). Donors of plasma for anti-D and anti-HBs production are tested for parvovirus B19 DNA.

[Analysis of the prevalence of HBV markers relevant to the risk of reactivation of infection in patients with hematologic diseases].

The study assessed the incidence of HBV markers (HBsAg, anti-HBc, anti-HBs) important for determination of the risk of reactivation of infection, with particular interest of occult infection (presence of HBV DNA in the absence of HBsAg) in patients treated at the Institute of Hematology and Transfusion Medicine. Anti-HBc frequency was correlated with the age and sex of patients. HBsAg was detected in 16/468 examined patients, 98/468 (21%) were anti-HBc positive.

Unexpected Course of [2+3] Cycloaddition of 2-nitropropene to (Z)-C,N-diphenylnitrone.

The [2+3] cycloaddition of 2-nitropropene to (Z)-C,N-diphenylnitrone leads to 3,4-trans-2,3-diphenyl-4-nitro-4-methyl- and 3,5-trans-2,3-diphenyl-5-nitro-5-methylisoxazolidines as primary reaction products. This, however, is not the only pathway of 2-nitropropene conversion. In the reaction conditions, the nitroalkene also undergoes isomerisation and the resulting trans- and cis-1-nitropropenes yield respective stereoisomeric 2,3-diphenyl-4-nitro-5-methylisoxazolidines in the reaction with (Z)-C,N-diphenylnitrone.

[Prevalence of HCV, HBV and HIV infections among severe Polish haemophiliacs].

Unlabelled: In the past, haemophilia replacement therapy was based on fresh frozen plasma, cryoprecipitate and blood transfusions--i.e. preparates not subjected to any viral inactivation methods.

[GBV-C/HGV and TTV infection markers in Polish blood donors and haemophilia patients].

Viruses GBV-C/HGV and TTV were identified in patients with hepatitis of unknown etiology. Aim of our study was to assess the frequency of infection markers of these viruses in blood donors and haemophilia patients treated with virucidaly activated and non inactivated blood products. Material and methods.

Characterization of HBV DNA+/HBsAg- blood donors in Poland identified by triplex NAT.

Nucleic acid testing (NAT) for hepatitis B virus (HBV) has been performed in Poland since 2005 on samples seronegative for hepatitis B surface antigen (HBsAg), anti-hepatitis C virus (anti-HCV), and anti-human immunodeficiency virus (anti-HIV). Tools included 24-donation pool testing (PT) using Cobas Amplicor or in individual donations (ID) by Procleix Ultrio. Seven of 761,666 (1:108,800) and 21/250,191 (1:11,900) HBV DNA-positive donations were identified and confirmed by alternative methods.

Hepatitis C core antigen in Polish blood donors.

Background: The goal of this study was to evaluate the feasibility of adopting the HCV core antigen ELISA (HCVcAg) for routine screening of Polish blood donors.

Study Design And Methods: A total of 133,279 donor samples were tested by ORTHO HCVcAg. All repeatedly reactive (RR) samples were tested by neutralization test for confirmation, RIBA HCV for anti-HCV, and by Cobas Amplicore for HCV RNA.